<div id="readability-page-1"><div><h2>Why AtaiBeckley’s Latest Earnings Matter For Investors</h2> <p>AtaiBeckley (ATAI) reported first quarter results showing a net loss of US$29.78 million, while basic and diluted loss per share from continuing operations improved to US$0.08 from US$0.15 a year earlier.</p> <p>See our latest analysis for AtaiBeckley.</p> <p>Following the earnings release, AtaiBeckley’s short term share price return has been positive, with a 3.36% 1 day move and a 9.21% 90 day gain. The 1 year total shareholder return of 125.54% suggests momentum has been building rather than fading.</p> <p>If AtaiBeckley’s recent move has you looking beyond a single stock, this may be a good time to broaden your search and check out 18 top founder-led companies</p> <p>With AtaiBeckley still reporting losses but showing an improved loss per share and strong recent returns, the key question is simple: is the stock still undervalued, or is the market already pricing in the future growth story?</p> <h2>Price To Book Of 7.7x: Is It Justified?</h2> <p>On traditional metrics, AtaiBeckley does not look cheap, with a P/B of 7.7x that sits well above both its industry and direct peer averages.</p> <p>The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a clinical stage biopharmaceutical stock with limited revenue and ongoing losses, a high P/B often reflects how much investors are willing to pay today for potential future drug pipelines rather than current earnings power.</p> <p>Here, AtaiBeckley’s 7.7x P/B is more than triple the US pharmaceuticals industry average of 2.1x and comfortably above the 5x peer average. That kind of premium indicates the market is assigning a considerable amount of value to its pipeline and growth prospects, even though the company is still unprofitable and does not yet have meaningful revenue.</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <p><strong>Result: Price to book ratio of 7.7x (OVERVALUED)</strong></p> <p>However, there are clear risks, including the company’s US$663.40 million net loss and the reality that multiple pipeline drugs are still in clinical trial stages.</p> <p>Find out about the key risks to this AtaiBeckley narrative.</p> <h2>Another View: DCF Paints A Different Picture</h2> <p>The high 7.7x P/B suggests AtaiBeckley is expensive, yet our DCF model points the other way. With the stock at $4.15 and a future cash flow value estimate of $6.01, it screens as undervalued by 30.9%. Which signal do you treat as more important?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/12666c18-393c-46e4-870e-b8b47d9c47db/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/12666c18-393c-46e4-870e-b8b47d9c47db/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE5"/><figcaption>ATAI Discounted Cash Flow as at May 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtaiBeckley for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>The mix of strong recent returns, losses, and a rich P/B can feel conflicting, so it makes sense to look at the numbers yourself and move quickly to form your own view based on where the risk and reward trade off sits. To help frame that balance, start with 2 key rewards and 3 important warning signs.</p> <h2>Looking For More Investment Ideas?</h2> <p>If you stop with one stock, you could miss out on setups that better match your risk tolerance, income needs, or growth goals.</p> <ul> <li>Spot potential underpriced opportunities early by checking out 51 high quality undervalued stocks that combine quality with attractive pricing.</li> <li>Strengthen the income side of your portfolio by reviewing 12 dividend fortresses built around higher yielding payouts.</li> <li>Sleep a little easier at night by reviewing 65 resilient stocks with low risk scores that focus on resilience and steadier fundamentals.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

ATAI

<p>AtaiBeckley (ATAI) reported a Q1 net loss of $29.78 million, but improved its loss per share to $0.08 from $0.15. Despite ongoing losses, the stock has seen a 3.36% one-day increase and a 9.21% gain over 90 days. The company's price-to-book ratio stands at 7.7x, indicating it may be overvalued compared to industry averages. However, a discounted cash flow analysis suggests it could be undervalued by 30.9%. Investors are advised to weigh risks and rewards carefully.</p>

Assessing AtaiBeckley (ATAI) Valuation After First Quarter Loss And Improved Per Share Results